The impact of ACE inhibition on all-cause and cardiovascular mortality in contemporary hypertension trials: A review

Expert Review of Cardiovascular Therapy

Volumn 11, Issue 6, 2013, Pages 705-717

  Ferrari, Roberto ^a   Boersma, Eric ^b  

^a UNIVERSITY HOSPITAL OF FERRARA   (Italy)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

ACE inhibitor; all cause mortality; angiotensin II; ARB; bradykinin; cardiovascular mortality; hypertension; meta analysis

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPROSARTAN; IMIDAPRIL; INDAPAMIDE; IRBESARTAN; LISINOPRIL; LOSARTAN; TELMISARTAN; VALSARTAN;

CARDIOVASCULAR MORTALITY; ENZYME INHIBITION; HUMAN; HYPERTENSION; META ANALYSIS (TOPIC); PREVALENCE; REVIEW;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; HUMANS; HYPERTENSION; RENIN-ANGIOTENSIN SYSTEM; RISK;

EID: 84878879515     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.13.42     Document Type: Review

References (67)

1. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 365(9455), 217-223 (2005).
2. Mancia G, De Backer G, Dominiczak A et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur. Heart J. 28(12), 1462-1536 (2007).
3. Wong ND, Dede J, Chow VH, Wong KS, Franklin SS. Global cardiovascular risk associated with hypertension and extent of treatment and control according to risk group. Am. J. Hypertens. 25(5), 561-567 (2012).
4. Graham I, Atar D, Borch-Johnsen K et al.; European Society of Cardiology (ESC) Committee for Practice Guidelines (CPG). European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). Eur. Heart J. 28(19), 2375-2414 (2007).
5. Cohn LD, Becker BJ. How meta-analysis increases statistical power. Psychol. Methods 8(3), 243-253 (2003).
6. van Vark LC, Bertrand M, Akkerhuis KM et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients. Eur. Heart J. 33(16), 2088-2097 (2012).
7. Wing LM, Reid CM, Ryan P et al.; Second Australian National Blood Pressure Study Group. A comparison of outcomes with angiotensin-converting enzyme inhibitors and diuretics for hypertension in the elderly. N. Engl. J. Med. 348(7), 583-592 (2003).
8. Yui Y, Sumiyoshi T, Kodama K et al.; Japan Multicenter Investigation for Cardiovascular Diseases-B Study Group. Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) randomized trial. Hypertens. Res. 27(3), 181-191 (2004).
9. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288, 2981-2997 (2002).
10. Bulpitt CJ, Beckett NS, Cooke J et al.; Hypertension in the Very Elderly Trial Working Group. Results of the pilot study for the Hypertension in the Very Elderly Trial. J. Hypertens. 21(12), 2409-2417 (2003).
11. Dahlöf B, Sever PS, Poulter NR et al.; ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 366(9489), 895-906 (2005).
12. Patel A, MacMahon S, Chalmers J et al.; ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with Type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 370(9590), 829-840 (2007).
13. Beckett NS, Peters R, Fletcher AE et al.; HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N. Engl. J. Med. 358(18), 1887-1898 (2008).
14. Lithell H, Hansson L, Skoog I et al.; SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J. Hypertens. 21(5), 875-886 (2003).
15. Ogihara T, Fujimoto A, Nakao K, Saruta T; CASE-J Trial Group. ARB candesartan and CCB amlodipine in hypertensive patients: the CASE-J trial. Expert Rev. Cardiovasc. Ther. 6(9), 1195-1201 (2008).
16. Kasanuki H, Hagiwara N, Hosoda S et al.; HIJ-CREATE Investigators. Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE). Eur. Heart J. 30(10), 1203-1212 (2009).
17. Schrader J, Lüders S, Kulschewski A et al.; MOSES Study Group. Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 36(6), 1218-1226 (2005).
18. Lewis EJ, Hunsicker LG, Clarke WR et al.; Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to Type 2 diabetes. N. Engl. J. Med. 345(12), 851-860 (2001).
19. Brenner BM, Cooper ME, de Zeeuw D et al.; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with Type 2 diabetes and nephropathy. N. Engl. J. Med. 345(12), 861-869 (2001).
20. Dahlöf B, Devereux RB, Kjeldsen SE et al.; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359(9311), 995-1003 (2002).
21. Yusuf S, Diener HC, Sacco RL et al.; PRoFESS Study Group. Telmisartan to prevent recurrent stroke and cardiovascular events. N. Engl. J. Med. 359(12), 1225-1237 (2008).
22. Yusuf S, Teo K, Anderson C et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 372, 1174-1183 (2008).
23. Julius S, Kjeldsen SE, Weber M et al.; VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363(9426), 2022-2031 (2004).
24. Mochizuki S, Dahlöf B, Shimizu M et al.; Jikei Heart Study group. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet 369(9571), 1431-1439 (2007).
25. McMurray JJ, Holman RR, Haffner SM et al. Effect of valsartan on the incidence of diabetes and cardiovascular events. N. Engl. J. Med. 362, 1477-1490 (2010).
26. Probstfield JL, O'Brien KD. Progression of cardiovascular damage: the role of renin-angiotensin system blockade. Am. J. Cardiol. 105(Suppl. 1), 10A-20A (2010).
27. Chrysant SG, Chrysant GS, Chrysant C, Shiraz M. The treatment of cardiovascular disease continuum: focus on prevention and RAS blockade. Curr. Clin. Pharmacol. 5(2), 89-95 (2010).
28. Strauss MH, Hall AS. Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox. Circulation 114(8), 838-854 (2006).
29. Bangalore S, Kumar S, Wetterslev J, Messerli FH. Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential analyses of 147 020 patients from randomised trials. BMJ 342, d2234 (2011).
30. Yusuf S, Teo KK, Pogue J et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med. 358, 1547-1559 (2008).
31. Barnett AH, Bain SC, Bouter P et al.; Diabetics Exposed to Telmisartan and Enalapril Study Group. Angiotensin-receptor blockade versus converting-enzyme inhibition in Type 2 diabetes and nephropathy. N. Engl. J. Med. 351(19), 1952-1961 (2004).
32. McDonald MA, Simpson SH, Ezekowitz JA, Gyenes G, Tsuyuki RT. Angiotensin receptor blockers and risk of myocardial infarction: systematic review. BMJ 331(7521), 873 (2005).
33. Verdecchia P, Angeli F, Gattobigio R, Reboldi GP. Do angiotensin II receptor blockers increase the risk of myocardial infarction? Eur. Heart J. 26(22), 2381-2386 (2005).
34. Volpe M, Mancia G, Trimarco B. Angiotensin II receptor blockers and myocardial infarction: deeds and misdeeds. J. Hypertens. 23(12), 2113-2118 (2005).
35. Turnbull F, Neal B, Pfeffer M et al. Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. J. Hypertens. 25, 951-958 (2007).
36. Ferrari R, Fox K. Insight into the mode of action of ACE inhibition in coronary artery disease: the ultimate 'EUROPA' story. Drugs 69(3), 265-277 (2009).
37. Unger T, Stoppelhaar M. Rationale for double renin-angiotensin- aldosterone system blockade. Am. J. Cardiol. 100(3A), 25J-31J (2007).
38. Athyros VG, Mikhailidis DP, Kakafika AI, Tziomalos K, Karagiannis A. Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution? Expert Opin. Pharmacother. 8(5), 529-535 (2007).
39. Naruse M, Tanabe A, Sato A et al. Aldosterone breakthrough during angiotensin II receptor antagonist therapy in stroke-prone spontaneously hypertensive rats. Hypertension 40(1), 28-33 (2002).
40. Segall L, Covic A, Goldsmith DJ. Direct renin inhibitors: the dawn of a new era, or just a variation on a theme? Nephrol. Dial. Transplant. 22(9), 2435-2439 (2007).
41. Wolf G, Ritz E. Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. Kidney Int. 67(3), 799-812 (2005).
42. Hollenberg NK, Fisher ND. Renal circulation and blockade of the renin-angiotensin system. Is angiotensinconverting enzyme inhibition the last word? Hypertension 26(4), 602-609 (1995).
43. Ceconi C, Francolini G, Olivares A, Comini L, Bachetti T, Ferrari R. Angiotensin-converting enzyme (ACE) inhibitors have different selectivity for bradykinin binding sites of human somatic ACE. Eur. J. Pharmacol. 577(1-3), 1-6 (2007).
44. Comini L, Bachetti T, Cargnoni A et al. Therapeutic modulation of the nitric oxide: all ace inhibitors are not equivalent. Pharmacol. Res. 56(1), 42-48 (2007).
45. Kim MP, Zhou M, Wahl LM. Angiotensin II increases human monocyte matrix metalloproteinase-1 through the AT2 receptor and prostaglandin E2: implications for atherosclerotic plaque rupture. J. Leukoc. Biol. 78(1), 195-201 (2005).
46. Guang C, Phillips RD, Jiang B, Milani F. Three key proteases-angiotensin- I-converting enzyme (ACE), ACE2 and renin-within and beyond the renin-angiotensin system. Arch. Cardiovasc. Dis. 105(6-7), 373-385 (2012).
47. Fraga-Silva RA, Da Silva DG, Montecucco F et al. The angiotensin- converting enzyme 2/angiotensin-(1-7)/Mas receptor axis: a potential target for treating thrombotic diseases. Thromb. Haemost. 108(6), 1089-1096 (2012).
48. Physicians' Desk Reference (58th Edition). Medical Economics Company, Montvale, NJ, USA (2004).
49. Morgan T, Anderson A. Duration of antihypertensive effect of perindopril (P), enalapril (E) and captopril (C). Hypertension 21, 568 (1993).
50. Manisty CH, Zambanini A, Parker KH et al.; Anglo-Scandinavian Cardiac Outcome Trial Investigators. Differences in the magnitude of wave reflection account for differential effects of amlodipine-versus atenolol-based regimens on central blood pressure: an Anglo-Scandinavian Cardiac Outcome Trial substudy. Hypertension 54(4), 724-730 (2009).
51. Williams B, Lacy PS, Thom SM et al.; CAFE Investigators; Anglo-Scandinavian Cardiac Outcomes Trial Investigators; CAFE Steering Committee and Writing Committee. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 113(9), 1213-1225 (2006).
52. Dolan E, Stanton AV, Thom S et al.; ASCOT Investigators. Ambulatory blood pressure monitoring predicts cardiovascular events in treated hypertensive patient-an Anglo-Scandinavian cardiac outcomes trial substudy. J. Hypertens. 27(4), 876-885 (2009).
53. Ferrari R. Angiotensin-converting enzyme inhibition in cardiovascular disease: evidence with perindopril. Expert Rev. Cardiovasc. Ther. 3(1), 15-29 (2005).
54. Louis WJ, Conway EL, Krum H et al. Comparison of the pharmacokinetics and pharmacodynamics of perindopril, cilazapril and enalapril. Clin. Exp. Pharmacol. Physiol. Suppl. 19, 55-60 (1992).
55. Julius S, Cohn JN, Neutel J et al. Antihypertensive utility of perindopril in a large, general practice-based clinical trial. J. Clin. Hypertens. (Greenwich) 6(1), 10-17 (2004).
56. Guo W, Turlapaty P, Shen Y et al. Clinical experience with perindopril in patients nonresponsive to previous antihypertensive therapy: a large US community trial. Am. J. Ther. 11(3), 199-205 (2004).
57. Tsoukas G, Anand S, Yang K; CONFIDENCE Investigators. Dose-dependent antihypertensive efficacy and tolerability of perindopril in a large, observational, 12-week, general practice-based study. Am. J. Cardiovasc. Drugs 11(1), 45-55 (2011).
58. Yazawa H, Miyachi M, Furukawa M et al. Angiotensin-converting enzyme inhibition promotes coronary angiogenesis in the failing heart of Dahl salt-sensitive hypertensive rats. J. Card. Fail. 17(12), 1041-1050 (2011).
59. Ceconi C, Fox KM, Remme WJ et al.; EUROPA Investigators; PERTINENT Investigators and the Statistical Committee. ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT. Cardiovasc. Res. 73(1), 237-246 (2007).
60. Cangiano E, Marchesini J, Campo G et al. ACE inhibition modulates endothelial apoptosis and renewal via endothelial progenitor cells in patients with acute coronary syndromes. Am. J. Cardiovasc. Drugs 11(3), 189-198 (2011).
61. Asmar R, Topouchian J, Pannier B, Benetos A, Safar M; Scientific, Quality Control, Coordination and Investigation Committees of the Complior Study. Pulse wave velocity as endpoint in large-scale intervention trial. The Complior study. Scientific, Quality Control, Coordination and Investigation Committees of the Complior Study. J. Hypertens. 19(4), 813-818 (2001).
62. Tropeano AI, Boutouyrie P, Pannier B et al. Brachial pressure-independent reduction in carotid stiffness after long-term angiotensin-converting enzyme inhibition in diabetic hypertensives. Hypertension 48(1), 80-86 (2006).
63. Savarese G, Costanzo P, Cleland JG et al. A meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure. J. Am. Coll. Cardiol. 61(2), 131-142 (2013).
64. Ruschitzka F, Taddei S. Angiotensin-converting enzyme inhibitors: first-line agents in cardiovascular protection? Eur. Heart J. 33(16), 1996-1998 (2012).
65. Cockcroft JR. ACE inhibition in hypertension: focus on perindopril. Am. J. Cardiovasc. Drugs 7(5), 303-317 (2007).
66. Chobanian AV, Bakris GL, Black HR et al.; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42(6), 1206-1252 (2003).
67. Powers BJ, Crowley MJ, McCrory DC et al. Future Research Needs for Angiotensin-Converting Enzyme Inhibitors (ACEIs), Angiotensin II Receptor Antagonists (ARBs), or Direct Renin Inhibitors (DRIs) for treating hypertension. Agency for Healthcare Research & Quality, Rockville, MD, USA (2012).